Fig. 2
From: Efficacy of MEK inhibitors in Erdheim-Chester disease: impact of MAPK pathway pathogenic variants
Progression-free survival for patients according to MAPK-ERK pathway mutation status.
Fig. 2 | Leukemia
From: Efficacy of MEK inhibitors in Erdheim-Chester disease: impact of MAPK pathway pathogenic variants
Progression-free survival for patients according to MAPK-ERK pathway mutation status.
